Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision Medicine Approach For Obesity with Semaglutide
NCT06814938Phase 4Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Feb 2025
- Primary completion
- Dec 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of semaglutide in obesity, sponsored by Mayo Clinic. Started Feb 2025; status: active, not recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06814938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06814938.